COSMOS Pharmaceutical Corporation
CSMYF · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.63 | -0.51 | 4.11 | -0.73 |
| FCF Yield | -0.16% | -0.10% | 2.87% | -4.51% |
| EV / EBITDA | 7.97 | 11.06 | 4.85 | 4.61 |
| Quality | ||||
| ROIC | 9.47% | 8.47% | 9.37% | 10.23% |
| Gross Margin | 21.09% | 19.51% | 20.38% | 20.05% |
| Cash Conversion Ratio | 1.24 | 2.26 | 1.66 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.91% | 8.50% | 4.45% | 3.35% |
| Free Cash Flow Growth | -35.28% | -108.14% | 168.99% | -724.13% |
| Safety | ||||
| Net Debt / EBITDA | -0.11 | -0.34 | -0.55 | -0.58 |
| Interest Coverage | 159.07 | 318.19 | 590.75 | 573.00 |
| Efficiency | ||||
| Inventory Turnover | 8.64 | 9.01 | 8.51 | 9.10 |
| Cash Conversion Cycle | -34.37 | -39.27 | -41.15 | -38.83 |